For the quarter ending 2025-09-30, CCCC has $265,488K in assets. $111,080K in debts. $58,809K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 58,809 | 78,157 | ||
| Marketable securities, current | 133,075 | 136,397 | ||
| Accounts receivable | 6,542 | 2,158 | ||
| Prepaid expenses and other current assets | 8,438 | 8,017 | ||
| Total current assets | 206,864 | 224,729 | ||
| Marketable securities, non-current | 7,875 | 8,419 | ||
| Property and equipment, net | 5,134 | 5,540 | ||
| Right-of-use asset | 41,961 | 54,218 | ||
| Restricted cash | 3,443 | 3,443 | ||
| Other assets | 211 | 178 | ||
| Total assets | 265,488 | 296,527 | ||
| Accounts payable | 1,333 | 2,216 | ||
| Accrued expenses and other current liabilities | 11,270 | 13,554 | ||
| Deferred revenue, current | 17,126 | 22,620 | ||
| Operating lease liability, current | 6,216 | 6,066 | ||
| Total current liabilities | 35,945 | 44,456 | ||
| Deferred revenue, net of current | 19,888 | 21,150 | ||
| Operating lease liability, net of current | 55,247 | 56,857 | ||
| Total liabilities | 111,080 | 122,463 | ||
| Common stock, par value of 0.0001 per share 300,000,000 and 150,000,000 shares authorized as of september30, 2025, and december31, 2024, respectively, and 74,174,515 and 70,625,899 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 7 | 7 | ||
| Additional paid-in capital | 872,521 | 860,128 | ||
| Accumulated other comprehensive income | 87 | -30 | ||
| Accumulated deficit | -718,207 | -686,041 | ||
| Total stockholders equity | 154,408 | 174,064 | ||
| Total liabilities and stockholders equity | 265,488 | 296,527 | ||
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)